Five Former CMS Chiefs Are Now on Big Pharma or PBM Boards
When CVS finalized its $69 billion Aetna acquisition, most headlines focused on the deal’s sheer scale. But another telling detail almost slipped by unnoticed: a former Centers for Medicare & Medicaid Services (CMS) Administrator quietly joined the company’s board. At this point, it’s almost routine. In 2024, five past CMS or FDA leaders now sit on boards or occupy C-suite roles at the country’s largest PBMs or the pharmaceutical giants negotiating with them. The math is straightforward, Fortune 50 PBM board seats offer annual compensation ranging from $300,000 to $500,000. And for departing government execs transitioning into policy roles, equity packages can outstrip a decade’s worth of federal paychecks within just a couple of years. The gravitational pull is real.
This revolving door isn’t new. Recruiters for UnitedHealth’s OptumRx division almost exclusively favor candidates with federal regulatory or Capitol Hill experience; the last three government affairs chiefs there all came straight from public posts. Express Scripts, meanwhile, seeks out Medicaid directors in states where it’s landed big contract wins. And sometimes the flow reverses. PBM pricing strategists hop to HHS or CMS, called to write or police the same rebate rules they previously profited from. No subtlety here, a 2023 industry survey showed over 40% of senior PBM leaders previously served in government. Pipeline? More like a four-lane highway.
PBM Profit Models: Policy Expertise at the Core
Spread pricing, still the sector’s most durable profit lever, didn’t just evolve naturally. Deep regulatory familiarity let PBMs ratchet up spread fees from 0.5% to 2.5% of claims in under ten years, as revealed by audit data in recent lawsuits. The minds behind these models had an edge: not only did they find every audit loophole, they also crafted the public messaging to keep pressure at bay. You’ll notice it in products like CVS Caremark’s “cost-plus” employer deals, which often trace back to architects of CMS transparency frameworks from just a few years before.
It’s not just a private sector playbook. Oversight staff who once tallied PBM rebate flows now run the agencies interpreting anti-kickback statutes. The line between referee and participant sometimes evaporates, for example, a top Express Scripts exec joined HHS OIG in 2018, only to resurface as a PBM audit director two years later. This isn’t speculation. The draft federal rule on rebate pass-throughs? It uses language first coined in PBM lobbying documents, their phrasing adopted, verbatim at times, by former insiders now crafting policy.
The money trail is hardly subtle. The first year CMS tested its direct-to-pharmacy reimbursement audits, PBM gross profit per Medicare script ticked down by just $0.47. Spread revenue snapped right back the next year, driven by new contract language penned by former CMS consultants. Want the day-by-day numbers? RxPBM.ai tracks PBM profit behavior in detail. Sometimes too much detail.
Regulatory Vacuums: What Happens When Industry Alumni Step Away
Leadership changes trigger predictable consequences, regulatory slowdowns, quieter enforcement. When a freshly hired CMS pharmacy director arrives straight from a PBM or its consulting wing, the pace slackens. No accident. In 2022, multiple states effectively paused investigations into PBM spread pricing after top regulatory staff left for jobs with managed care companies under scrutiny. The pattern couldn’t be clearer: an audit warning lands, then quietly evaporates when the lead official’s departure to the private sector is announced.
Employers and pharmacies feel the impact straight away. Every delay in spread-pricing audits means higher prescription costs for businesses, sometimes $3 to $7 extra per fill while paperwork sits idle. Pharmacies? They often watch reimbursement dip below drug acquisition costs, stuck waiting for retroactive fixes as ex-regulators transition to their PBM posts. In this churn, standards drift. Promised rules get published, then reinterpreted by the familiar faces now sitting across the negotiating table.
From Rulemaker to Strategist: The Industry’s Most Prized Skill Set
What happens when a regulator becomes a PBM strategist? Their value skyrockets, because they know precisely which enforcement levers regulators are unlikely to pull. Take the surge in “administrative fees” that replaced rebates after the 2020 rule shakeup. In less than 18 months, a cadre of ex-CMS and HHS staff at the major PBMs retooled contracts to grow admin fees from 0.9% to 2% of claims. Even as transparency rules rolled out, PBM revenue remained insulated. Most employers, without forensic compliance teams, don’t spot the change until rebates dry up and plan costs climb. For detailed employer case studies, RxBenefits.ai is worth a browse.
Specialty drug pricing? An even tighter circle. Biosimilar launches should make drugs cheaper. But former FDA and PBM execs, now advising both sides, steer biosimilar adoption slowdowns while fine-tuning step therapy rules to keep rebate streams healthy. In 2023, adalimumab biosimilars were technically available, but three top PBMs still favored the pricey reference product, citing “clinical guidance” ghostwritten by agency alumni now wearing consulting hats.
Is it intentional? In this sector, almost no one's career zigzags by accident. The revolving door flips the advantage in every negotiation, buyers rarely win, and patients? They’re mostly an afterthought in these calculus sessions. Reforms might promise answers, but those answers end up rewritten in the very conference rooms where yesterday’s regulator is today’s strategist. And if this all sounds circular, well, that’s real life in the drug pricing trenches.
